P/E ratio for Cormedix (CRMD)
P/E ratio as of May 2024 (TTM): -6.24
According to Cormedix's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.24419. At the end of 2022 the company had a P/E ratio of -5.70.
P/E ratio history for Cormedix from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.70 | -7.25% |
| 2021 | -6.15 | -37.11% |
| 2020 | -9.78 | 143.06% |
| 2019 | -4.02 | 2.27% |
| 2018 | -3.93 | 379.82% |
| 2017 | -0.8197 | -66.25% |
| 2016 | -2.43 | -28.22% |
| 2015 | -3.38 | 89.54% |
| 2014 | -1.79 | -0.67% |
| 2013 | -1.80 | -25.12% |
| 2012 | -2.40 | 397.14% |
| 2011 | -0.4828 | 68.97% |
| 2010 | -0.2857 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Becton Dickinson BDX | 43.3 | -793.55% | 🇺🇸 USA |
 Utah Medical Products UTMD | 14.5 | -331.61% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | -0.2732 | -95.63% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.